programmed cell death 6Genealiases: ALG-2 · ALG2 · PEF1B
Q-omics provides the consensus-scored PDCD6 profile across patient tissues and cancer cell-line models. PDCD6 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PDCD6 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, PDCD6 RNA expression shows 19,440 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where PDCD6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDCD6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDCD6 survival associations across molecular data types. PDCD6 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDCD6 RNA expression–survival associations across cancer types. High PDCD6 expression shows unfavorable associations in UVM, KICH, LIHC, KIRP and CESC, but favorable associations in BLCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PDCD6 RNA expression.
This table summarizes PDCD6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PDCD6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDCD6 shows higher tumor expression in KIRC, HNSC, KIRP, LIHC, LUAD and COAD. The KIRC box plot shows higher PDCD6 RNA expression in tumor versus normal tissue (log2 FC = +0.966, t-test p < 0.001).
This table shows molecular features associated with PDCD6 in patient tissues and cancer cell lines. In patient samples, PDCD6 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PDCD6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and UPPER_AERODIGESTIVE_TRACT.
